Jubilant Biosys has added Agilent Technologies’ RapidFire/MS screening technology to its drug discovery platform.
 
RapidFire is a solid phase extraction technology that enables label-free detection of native compounds by mass spectrometry in a wide range of in vitro assays, DMPK/ADME studies, hit/lead applications for drug discovery, as well as screening difficult targets that are not amenable to labeled assays. Jubilant’s Bengaluru facility will be the first in India to be equipped with the RapidFire High-Throughput Mass Spectrometry system technology.
 
“The installation of the Agilent RapidFire platform shows Jubilant’s continued commitment to make the necessary investments with an objective to remain on the cutting edge of drug discovery. This platform will enable us to increase our productivity and to enhance our capabilities to successfully meet the needs of our clients,” said Steven Hutchins, president, Jubilant Biosys.
 
“Agilent RapidFire solution enables our clients with increased accuracy, provides faster results, better economic value, enhanced analysis capabilities, improved efficiency while maintaining robustness and we are pleased to see Jubilant Biosys being the first organization in India to take advantage of this cutting-edge technology,” said Bharat Bhardwaj, country manager, Agilent Technologies.